North America vs Tajikistan: Prevalence of hypertension, female
North America
28.0%
in 2019
Tajikistan
42.8%
in 2019
North America rank
37th
Tajikistan rank
39th
Prevalence of hypertension, female over time
- North America
- Tajikistan
How they compare
Tajikistan currently reports 42.8% against 28.0% in North America, a difference of 14.8%.
That makes Tajikistan's figure about 1.5 times North America's.
Across all 30 years both countries report, Tajikistan has been ahead every year.
North America ranks 37th and Tajikistan ranks 39th of 43 groups.
Tajikistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | North America | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 28.8% | 41.3% | 12.5% | Tajikistan |
| 2000s | 29.3% | 42.9% | 13.6% | Tajikistan |
| 2010s | 28.6% | 43.5% | 14.9% | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hypertension, female, North America or Tajikistan?
- Tajikistan, at 42.8% against 28.0% in North America as of 2019.
- What is the difference in prevalence of hypertension, female between North America and Tajikistan?
- 14.8%, with Tajikistan ahead.
- How many years of comparable data are there for North America and Tajikistan?
- 30 years are reported by both, from 1990 to 2019.
- How do North America and Tajikistan rank globally for prevalence of hypertension, female?
- North America ranks 37th and Tajikistan ranks 39th of 43 groups.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Prevalence of hypertension, female (% of female adults ages 30-79). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Prevalence of hypertension, female, is the percentage of female adults ages 30-79 with hypertension (defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension). The data is age-standardized.